Literature DB >> 17329016

Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.

Abdulmaged M Traish1, Irwin Goldstein, Noel N Kim.   

Abstract

OBJECTIVES: Androgens are essential for the development and growth of the penis, and they regulate erectile physiology by multiple mechanisms. Our goal is to provide a concise overview of the basic research and how this knowledge can be translated into a new clinical paradigm for patient management. In addition, this new paradigm may serve as a basis for stimulating constructive debate regarding the use of testosterone in men, and to promote new, innovative basic and clinical research to further understand the underlying mechanisms of androgen action in restoring erectile physiology.
METHODS: A literature review was performed utilizing the US National Library of Medicine's PubMed database.
RESULTS: On the basis of evidence derived from laboratory animal studies and clinical data, we postulate that androgen insufficiency disrupts cellular-signaling pathways and produces pathologic alterations in penile tissues, leading to erectile dysfunction. In this review, we discuss androgen-dependent cellular, molecular, and physiologic mechanisms modulating erectile function in the animal model, and the implication of this knowledge in testosterone use in the clinical setting to treat erectile dysfunction. The new clinical paradigm incorporates many of the consensed points of view discussed in traditional consensed algorithms exclusively designed for men with androgen insufficiency. There are, however, novel and innovative differences with this new clinical paradigm. This paradigm represents a fresh effort to provide mandatory and optional management strategies for men with both androgen insufficiency and erectile dysfunction.
CONCLUSIONS: The new clinical paradigm is evidence-based and represents one of the first attempts to address a logical management plan for men with concomitant hormonal and sexual health concerns.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329016      PMCID: PMC2562639          DOI: 10.1016/j.eururo.2007.02.034

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  163 in total

1.  Summary of the recommendations on sexual dysfunctions in men.

Authors:  Tom F Lue; François Giuliano; Francesco Montorsi; Raymond C Rosen; Karl-Erik Andersson; Stanley Althof; George Christ; Dimitrios Hatzichristou; Mark Hirsch; Yasasuke Kimoto; Ronald Lewis; Kevin McKenna; Chris MacMahon; Alvaro Morales; John Mulcahy; Harin Padma-Nathan; John Pryor; Inigo Saenz de Tejada; Ridwan Shabsigh; Gorm Wagner
Journal:  J Sex Med       Date:  2004-07       Impact factor: 3.802

2.  Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.

Authors:  M Schubert; T Minnemann; D Hübler; D Rouskova; A Christoph; M Oettel; M Ernst; U Mellinger; W Krone; F Jockenhövel
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

Review 3.  Peripheral regulatory mechanisms in erection.

Authors:  A Morelli; S Filippi; X-H Zhang; M Luconi; L Vignozzi; R Mancina; M Maggi
Journal:  Int J Androl       Date:  2005-12

4.  Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

Authors:  Stephanie T Page; John K Amory; F Dubois Bowman; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover
Journal:  J Clin Endocrinol Metab       Date:  2004-11-30       Impact factor: 5.958

5.  Diagnostic steps in the evaluation of patients with erectile dysfunction.

Authors:  Dimitrios Hatzichristou; Konstantinos Hatzimouratidis; Michael Bekas; Apostolos Apostolidis; Vasilios Tzortzis; Konstantinos Yannakoyorgos
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

6.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 7.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

8.  Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction.

Authors:  Antonio Aversa; Andrea M Isidori; Giovanni Spera; Andrea Lenzi; Andrea Fabbri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

9.  Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?

Authors:  A T Guay; J Jacobson; J B Perez; M B Hodge; E Velasquez
Journal:  Int J Impot Res       Date:  2003-06       Impact factor: 2.896

10.  A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men.

Authors:  Paul D Morris; Chris J Malkin; Kevin S Channer; T Hugh Jones
Journal:  Eur J Endocrinol       Date:  2004-08       Impact factor: 6.664

View more
  48 in total

Review 1.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

2.  The inter-relational effect of metabolic syndrome and sexual dysfunction on hypogonadism in type II diabetic men.

Authors:  N Amidu; W K B A Owiredu; C K Gyasi-Sarpong; H Alidu; B B Antuamwine; C Sarpong
Journal:  Int J Impot Res       Date:  2017-03-09       Impact factor: 2.896

3.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

Review 4.  Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction.

Authors:  Carol A Podlasek; John Mulhall; Kelvin Davies; Christopher J Wingard; Johanna L Hannan; Trinity J Bivalacqua; Biljana Musicki; Mohit Khera; Nestor F González-Cadavid; Arthur L Burnett
Journal:  J Sex Med       Date:  2016-08       Impact factor: 3.802

5.  Androgen depletion in humans leads to cavernous tissue reorganization and upregulation of Sirt1-eNOS axis.

Authors:  Inês Tomada; Nuno Tomada; Henrique Almeida; Delminda Neves
Journal:  Age (Dordr)       Date:  2011-11-04

6.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

7.  [Testosterone and erectile dysfunction].

Authors:  T Diemer
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 8.  Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials.

Authors:  Landon W Trost; John P Mulhall
Journal:  J Sex Med       Date:  2016-05-18       Impact factor: 3.802

9.  Improvement of the diabetic foot upon testosterone administration to hypogonadal men with peripheral arterial disease. Report of three cases.

Authors:  Svetlana Kalinchenko; Alexandr Zemlyanoy; Louis J Gooren
Journal:  Cardiovasc Diabetol       Date:  2009-03-28       Impact factor: 9.951

10.  The relationship of serum and salivary cortisol levels to male sexual dysfunction as measured by the International Index of Erectile Function.

Authors:  Y Kobori; E Koh; K Sugimoto; K Izumi; K Narimoto; Y Maeda; H Konaka; A Mizokami; T Matsushita; T Iwamoto; M Namiki
Journal:  Int J Impot Res       Date:  2009-05-07       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.